Progression-free Survival 96% in CLL With IbrutinibMedscapeJennifer Brown, MD, assistant professor in the Department of Medicine at Harvard Medical School in Cambridge, Massachusetts, presented interim data on ibrutinib in combination with bendamustine…
Universal HBV Screening Is Cost-Effective in LymphomaMedscapeIn patients who were going to receive rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy, screening all patients for HBV decreased the rate of HBV reac…
pharmabiz.com |
Dr Reddy’s Labs scrip outperforms BSEHC, touches yearly high of
pharmabiz.com DRL has already pushed four biosimilars viz, rituximab, filgrastim, darbepoetin alpha and peg-filgrastim in the market. To consolidate its position in biosimilars, DRL entered into an alliance with Merck Serono, a division of Merck KGaA, Germany during … |
|
UK man jailed for role in fake Avastin case
SecuringIndustry.com It was disclosed yesterday by the US Department of Justice (DoJ) that Taylor was also involved in illegal shipments of Roche’s Rituxan (rituximab), used to treat non-Hodgkin’s lymphoma and rheumatoid arthritis. “This sentence aptly reflects the serious … |
|
Janssen whizzes promising CLL agent over to regulators
Medical Marketing and Media Gilead’s candidate, idelalisib, was tested in combination with rituximab in treatment-naïve patients with CLL. That regimen achieved a compete response rate of 19% and an overall response rate of 97% in patients. AbbVie’s contender, ABT-199, which Yee … |
DRL bets big on biosimilarsTimes of IndiaThe company in its annual report 2013 said that it has already produced four biosimilars – rituximab called Reditux TM, filgrastim called Grafeel, darbepoetin alpha called Cresp and peg-filgrastim called Peg-Gra…
MedPage TodayCase of PML Linked to JakafiMedPage TodayMore recently, PML has struck patients treated with drugs targeting specific elements of the immune system, such as natalizumab (Tysabri), rituximab (Rituxan), and dimethyl fumarate (Fumaderm). Ruxo…
|
Radioimmunotherapy Deemed Safe and Effective for Lymphoma Patients
HealthCanal.com According to data published in the July issue of The Journal of Nuclear Medicine, the use of 177Lu-DOTA-rituximab as a radioimmunotherapy results in a high rate of tumor response while using less radiation than current therapies. “Twelve years ago … |
|
Radioimmunotherapy Deemed Safe And Effective For Lymphoma Patients
RedOrbit According to data published in the July issue of The Journal of Nuclear Medicine, the use of 177Lu-DOTA-rituximab as a radioimmunotherapy results in a high rate of tumor response while using less radiation than current therapies. “Twelve years ago, … |
|
Radioimmunotherapy deemed safe and effective for lymphoma patients
Science Codex According to data published in the July issue of The Journal of Nuclear Medicine, the use of 177Lu-DOTA-rituximab as a radioimmunotherapy results in a high rate of tumor response while using less radiation than current therapies. “Twelve years ago … |